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Abstract
The pharmaceutical care is a pharmacist’s contribution to the care of individual patients and leads to optimize the use of drugs. 
The pharmaceutical care may improve adherence, clinical effectiveness of providing therapy and improve the health-related 
quality of life. The conducted literature review confirmed that pharmaceutical care and advanced pharmaceutical services are 
clinical effective in asthma. The implementation of pharmaceutical care under Polish conditions is currently insufficient and 
remains challenging for the future. Herein we should admit, that the polish government has recently put an effort to appoint 
specially dedicated team establishing a program of reimbursed pharmaceutical care. This move should be considered as a new 
phase for amendments community pharmacy in Poland. The experience of different health care systems, including for instance 
United Kingdom, Australia or Canada, might be used in the process of changing Polish perspective. Herein, we have reviewed the 
literature and highlighted the services creating the program of pharmaceutical care in asthma. This unique work describes the 
complex nature of optimal pharmaceutical services emphasizing the strong necessity of multidimensional approach in this field.
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In the opinion of Polish experts, several 
factors including the low therapy adherence, 
inappropriate inhalation technique or insufficient 
symptom control using the available classes of 
medications, etc. essentially influence the cour-
se of asthma [1]. Adherence to therapy is one of 
the most critical conditions of successful  treat-
ment of asthma [2]. The high level of adherence 
is also one of the critical factors associated with 
good prognosis in the chronic disease [3]. Impro-
ving adherence remains challenging, and needs 
a well-designed and multi-approach attitude [4].
Asthma is a chronic inflammatory and re-
spiratory disease characterized by recurrent, 
reversible, episodes of shortness of breath, chest 
tightness, coughing, and wheezing. A large body 
of literature describes a high prevalence of asthma 
patients, i.e. 300 millions, in global perspective. 
Despite the availability of effective preventive 
therapy, the direct and indirect costs of manage-
ment of patients with asthma increase constantly 
[5, 6]. 
One of the well-known methods to improve 
adherence and control the expenditure associated 
with asthma is to include the pharmaceutical care 
into healthcare system. 
The aim of this article is to introduce the 
concept of pharmaceutical care as a list of servi-
ces provided by a pharmacist in a community 
pharmacy to patients diagnosed with asthma. The 
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services are selected for possible implementation 
in the Polish health care system. 
The promotion of the pharmaceutical care 
as a new approach of cooperation between he-
althcare practitioners and the promotion of the 
community pharmacy as a place of public health 
protection remains substantial for the successful 
development of new services.
Last but not least, the article describes the 
current situation of implementation of advanced 
pharmaceutical services in the community phar-
macy in Poland. Finally, the discussion highlights 
the possibility of introducing advanced pharma-
ceutical services into Polish community pharmacy.
The pharmaceutical care —  
the development of services
Over the years, the definition of pharma-
ceutical care has evolved. Finally, in 2013, was 
proposed the definition of pharmaceutical care 
as a pharmacist’s contribution to the care of in-
dividual patients, leading to optimize the use of 
drugs and improve health outcomes [7, 8]. In the 
practice pharmaceutical care is realized by a ran-
ge of services provided by pharmacists to patients, 
particularly suffering from chronic diseases. 
Among other services should be distinguished 
medications reviews. In line with Dutch guideli-
nes, a medication review is a structured critical 
examination of a patient’s medication, performed 
by a pharmacist to achieve an agreement with the 
patient about the management strategy, optimi-
zing the efficacy of the treatment, and minimizing 
the number of medication-related problems [9]. In 
the context of asthma should also be mentioned 
another pharmaceutical service - instructing the 
patient about proper using of inhalers [10]. The 
important is also the role of the pharmacist as 
an educator about the nature of the disease and 
healthy lifestyle [11]. Currently, in Poland only 
one of the various possible advanced pharmaceu-
tical services has been implemented — advising 
about side effects or interactions between the drug 
used in asthma and medicinal products available 
without physicians’ prescription (OTC, over the 
counter) [12]. Moreover, the quality of mentioned 
services is doubtful because the lack of well-e-
stablished standards [13]. Thus, in Polish health 
system pharmacists are the guardian of the quality 
of the drug e.g. ensures that medicinal products 
dispensed to patients were stored in appropriate 
conditions [14]. Analysis of the literature provi-
des scientific evidence confirming the clinical and 
cost effectiveness of pharmaceutical care [15]. 
The pharmaceutical care — the process of 
optimizing pharmacotherapy
The primary objective of pharmaceutical 
care is to optimize pharmacotherapy. One of the 
studies shows a tremendous role in the optimi-
zation of pharmacotherapy in patients diagnosed 
with asthma. The medication errors associated 
with asthma include, among others, using of 
non-selective b-blockers or using of long-acting 
b -agonists (LABA), without inhaled corticostero-
ids. The Danish study showed that approximately 
5,2% of the asthma patients are using b-blockers, 
and 21,8% of them received non-cardioselective 
b-blockers. 6,3% of the asthma patients were tre-
ated with two or more oral courses of corticoste-
roids in 2008, and 17,4% of these patients did not 
receive inhaled corticosteroids in 2009. Therefo-
re, optimization of pharmacotherapy should be 
based on finding medications’ errors. Moreover, 
pharmacists can target successfully pulmonary 
patients that were not treated according to the 
evidence-based guidelines [16]. This constitutes 
a great potential for pharmaceutical care [17].
Medication review may significantly reduce 
medication burden in geriatric population [18, 
19]. Because of the complexity of pharmacothe-
rapy in asthma, similar results for mentioned 
service should be strongly expected. Finally, 
pharmaceutical care programs showed a positive 
impact on improving patient’s asthma-related 
quality of life, lung function, and asthma control 
[20, 21].
The role of telemedicine  
in pharmaceutical services
The pharmaceutical research services are 
also conducted in the area of telemedicine, as 
being recognized as mHealth — mobile health. 
One of the analyzed studies presents the first 
intervention based on the mobile communication 
technology involving community pharmacists 
in asthma management. It shows the evolution 
of pharmaceutical services provided in the com-
munity pharmacy. ‘The Empowering pharmacist 
in asthma management through interactive SMS’ 
(EmPhAsIS) remains the system supporting 
pharmacists to provide effective pharmaceutical 
services. The EmPhAsIS intervention consists of 
asthma patient education, short message service 
(SMS)-based monthly assessment of adherence, 
and follow-up of non-adherent individuals by 
community pharmacists. The primary outcome is 
adherence to inhaled corticosteroids ascertained 
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by the medication possession ratio, the ratio of 
the days of medication supplied to days in a given 
time interval. This intervention may consequently 
provide the increase of the adherence [22]. 
Proper way to use inhalers
The most fundamental method of drug deli-
very in asthma is inhalation. The studies show 
that the adherence is mainly improved by advan-
ced services of well-trained pharmacists. From the 
methodological point of view, the participants’ 
inhaler technique remains critical and should 
be carefully assessed. Regardless of the teaching 
method used, (with or without visual feedback), 
pharmacists’ intervention increased substantially 
the number of patients using inhalers correctly. 
The study also affirms that above mentioned 
intervention should be enriched with illustrated 
materials dedicated to increasing patients edu-
cation [23]. 
Another study shows that inhalation tech-
nique and adherence to controller medication 
were significantly better in patients surrounded 
by the pharmaceutical care. The primary outcome 
was the level of asthma control, as assessed by 
the Asthma Control Test (ACT).The authors of 
this study simplify the pharmaceutical care to 
the correct use of inhalers. Unfortunately, this is 
not consistent with the current approach to phar-
maceutical care. Pharmaceutical care is a range 
of services leading to optimize pharmacotherapy 
what has been widely discussed hereinabove [24]. 
However, many patients are not aware of how 
helpful may be pharmacists’ support in asthma. 
The patients felt little need for the inhaler co-
unseling service. Patients, however, accepted the 
service for various reasons of which the feeling 
how staff showing an interest in helping them 
seemed especially convincing [25].
Screening test in the community pharmacy
Next study shows that less sophisticated 
pharmaceutical services also may be beneficial 
for the patients. Validated questionnaire e.g. Phar-
macy Asthma Control Screening tool (PACS) or 
Asthma Control Questionnaire (ACQ-6) should be 
used to access of patients’ adherence. This study 
describes a simple asthma control screening as 
a feasible tool for the use in the community phar-
macies, which has additionally a good sensitivity 
for identifying patients with not well-controlled 
asthma. These questionnaires are useful in pri-
mary care to identify patients who require more 
detailed examination of their asthma status and 
require more attention from physicians and phar-
macists. Due to this fact, providing questionnaire 
in the community pharmacy remains uncompli-
cated to improve patients’ adherence [26]. 
Health education in the community pharmacy
Combine the optimization of pharmacothera-
py with education about healthy lifestyle should 
be analyzed in the field of public health. In the 
UK or Canada, pharmacists play a key role in the 
promotion of immunization and in reducing the 
spread of infectious diseases [27]. These and other 
activities described in the article lead to the popu-
lation health improvement. In the coming years, 
the role of pharmacists and pharmacy community 
will probably increase in health promotion and 
prevention behaviors [28, 29].
Last but not least, a combination of education 
about the disease and education on the proper 
use of inhalers remains beneficial for the patients 
diagnosed with asthma. Adult asthma patients in 
the intervention group received a protocol-based 
intervention addressing individual needs related 
to asthma control, inhaler technique and medica-
tion adherence. The information provided to the 
patients is directly associated with the life-style 
and health education. The intervention resulted in 
improved medication adherence and inhaler tech-
nique. It is possible to combine different pharma-
ceutical services to improve clinical outcomes [30]. 
Education about the natural history of the 
disease is crucial in providing pharmaceutical 
services. Pharmacists may provide patient educa-
tion to explain the role of medications, to provide 
smoking cessation or to recommend strategies to 
minimize adverse effects of prescribed medica-
tions. ‘Asthma-Friendly Pharmacy’ is the model 
of integration pharmaceutical care with the care 
provided by another healthcare team member. 
Last but not least, pharmaceutical services in this 
program are beneficial for promoting interprofes-
sional collaboration in healthcare system [31].
Pharmacists should fulfill the needs of pa-
tients, find the medication error and detect inap-
propriate inhaler use. Australian research indi-
cated that pharmaceutical services are beneficial 
also in rural areas [32]. A national pharmacy-ba-
sed service in Australia (the PACP) for the care 
of patients with asthma resulted in improved 
clinical and humanistic outcomes. The mentio-
ned services indicated the improving the level 
of quality of life in patients surrounded by the 
pharmaceutical care [33]. 
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Pediatrician populations  
in the community pharmacy
So far, there is limited number of the clinical 
studies based on large patient cohorts. One study, 
including the large pediatric setting of Chicago 
presents a methodology of assessing the effect 
of large multi-component community interven-
tions for asthma, using administrative pharmacy 
data. The results suggest a beneficial effect on 
the quality of care in the subgroup of children 
with asthma targeted by the project [34]. The 
key role of adherence of pharmacists assistance 
to the pediatric guidelines has been highlighted 
in another interesting study depicting the strong 
need of active involvement of pharmacists in the 
asthma treatment in children [35]. 
Challenge for interprofessional collaboration
In the light of current knowledge, pharma-
cists who participate in the pharmaceutical care 
process show a higher level of satisfaction with 
their work [36]. This has been supported by the 
Australian experience. The pharmacists were 
engaged as research partners, recognizing their 
role as pioneers of a novel, clinically advanced 
service model for other Australian pharmacists 
[37]. Pharmaceutical care and advanced pharma-
ceutical services remain challenging and offer the 
interesting and effective way to promote inter-
professional collaboration between pharmacists 
and physicians. The advanced pharmaceutical 
services also need the changing of settings of 
the health care system [38]. The new standards 
and guidelines should be implemented and used 
effectively. 
Current situation in Poland
Currently, pharmaceutical care and advanced 
pharmaceutical services are not implemented into 
Polish community pharmacy. This paper descri-
bes current achievements of social and practice 
pharmacy in the context of pharmaceutical care 
in asthma. However, it should be noted that these 
services are not merely limited to asthma and 
might be extended to different chronic respiratory 
diseases e.g. chronic obstructive pulmonary dise-
ase. Authors are aware of difficulties associated 
with successful implementation the cognitive 
services into the routine settings. Particularly, 
two of these impediments are extremely impor-
tant. First relates to the legal issues, the second 
is related to the insufficient accomplishment of 
interprofessional collaboration between the phy-
sicians and pharmacists in Poland. In contrary, 
the recent study comparing the situation in Po-
land and UK has shown that the implementation 
of pharmaceutical care may essentially help to in-
crease patient loyalty and consequently enhance 
the competitiveness of pharmacies [39].
Of note, currently, in Poland, the role of the 
pharmacist has been limited to dispense medi-
cines and to provide short advice concerning 
medical related problems. This state lasts despite 
the fact that pharmaceutical care was introduced 
to the Polish law in 2008 with the amendment to 
the Act on Chambers of Pharmacists (pl. Ustawa 
o  izbach aptekarskich, Dz. U. 1991 Nr 41 poz. 
179). As highlighted previously, the populari-
zation of interprofessional collaboration is the 
prerequisite in the process of implementation 
of pharmaceutical care in Poland. This process 
should be launched in concert with the under-
graduate training and, subsequently continued 
in the postgraduate education. The future should 
bring enhanced efforts of all relevant stakeholders 
in the dissemination of the concept of interpro-
fessional collaboration, predominantly from the 
practical point of view. 
To effectively implement the cognitive servi-
ces, legal-related issues should be resolved, parti-
cularly these related to the medical information. 
For this, pharmacists need to have access to the 
patients’ medical history. So far, physicians can-
not transfer information about the health status 
of the patient to the pharmacist. These factors 
make the process of conducting pharmaceutical 
care under the conditions of the Polish healthcare 
system difficult and ineffective. Currently, from 
the legal point of view, information obtained 
through the pharmaceutical care process from 
e.g. medication reviews, can be submitted to the 
physicians only after obtaining the direct patients’ 
consent. Of note, the implementation of advanced 
pharmaceutical services should be understood 
in the context of the barriers and impediments 
to the efficient proliferation of pharmaceutical 
care into community pharmacies settings. Firstly, 
patients should be ensured that the pharmaceuti-
cal care is conducted in the private and intimate 
atmosphere. Hence, there is strong need to create 
the professional area mainly dedicated to more 
insightful relations with patients. Consequently, 
the organizational structure of community phar-
macies should be arranged on a de novo basis, e.g. 
the new professional staff should be recruited and 
adjusted to more cognitive duties. From the aca-
demic point of view, changes in pharmaceutical 
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practice should be supported by the postgradu-
ate training, also in the scope of soft skills and 
communication abilities. Finally, one of the most 
significant factors contributed to the process of 
the successful implementation of pharmaceutical 
care under Polish conditions is the collaboration 
between pharmacists and primary care physi-
cians. The introduction of more advanced role of 
community pharmacists in the healthcare system 
should be provided in line with direct cooperation 
with family medicine specialists. For instance, 
some of the pharmaceutical or medical meetings 
might be considered as the opportunity of joint 
discussion. On the other hand, indispensable in 
the process of providing pharmaceutical care is 
to promote the specialized computer assistance. 
This topic has been already widely discussed in 
light of the implementation of falsified directive 
[14]. Currently, the wide range of interactive 
websites with the applied tools are launched, 
also in Poland. The milestone would be to create 
the interactive platform where the pharmacists 
and physicians could transfer the patient-related 
information. This medium is, indeed, one of the 
fundamental pillars of e-health services. The fi-
nancial matter should be resolved before the full 
implementation of new services. Furthermore, the 
pharmaceutical care is dedicated to chronic and 
elderly populations. Hence, the services should 
be reimbursed from public sources. Otherwise, 
the widespread of these services will be rather 
marginal. All these factors remain a significant 
challenge to the community of healthcare profes-
sionals, and, on the other hand, for the politicians 
responsible for the healthcare system in Poland.
So far, the research on pharmaceutical care in 
Poland has been limited to the setting of hyperten-
sion. Patients who participated in the pharmaceu-
tical care had the proper blood pressure (achieved 
in 79% cases, p < 0.05). Accordingly, the patients 
who did not participate in this programachieved 
the proper value in 55% of cases. Skowron et al. 
also showed that pharmaceutical care improves 
the level of patients’ knowledge about hyperten-
sion [40]. Although the authors put their effort 
to perform an objective and precise search, no 
studies describing the pharmaceutical care in 
asthma in Poland has been identified.
Scientific evidence proves beyond doubt 
the clinical effectiveness of pharmaceutical care 
for patients with asthma. According to Drozd 
et al pharmaceutical care under the conditions 
of Polish health care system should focus on 
technical advice regarding the correct usage 
of inhalers, information about anti-asthmatic 
drugs, effects-focused therapy advice for pa-
tients, comprehensive monitoring of therapy 
results [41].
Perspectives on implementation to polish 
healthcare system, as well as the advanced and 
new pharmaceutical services are summarized in 
Table 1. In the opinion of the authors of this work, 
services easy to be implemented into the Polish 
healthcare include the following: the advisory in 
Table 1. Perspectives on implementation advanced and new pharmaceutical services to Polish healthcare system 
Services Impact  
on adherence
Impact  
on health-related 
quality of life
The perspective of implementation to Polish heal-
thcare system
1 Short message service (SMS-based 
intervention)
Increase Increase Difficult, from legal point of view currently unavaila-
ble service
2 Advising about the correct use of in-
halers
Increase Increase Possible to implement to Polish healthcare system. 
Need to prepare the standardization of advising
3 Using validating test to assess the asth-
ma control profile
Increase Increase Possible to implement to Polish healthcare system
4 Education about pro healthy lifestyle Increase Increase Possible to implement to Polish healthcare system
5 Pharmaceutical care among pediatrician 
population
Increase Increase Hard to be implemented
Changing the law is necessary Necessary is to incre-
ase the level of knowledge in the field of pediatrician 
pharmacotherapy among Polish pharmacists
6 Medication reviews Increase Increase Possible to implement to Polish healthcare system.
7 Advising about side effects or interac-
tions between the drug used in asthma 
and medicinal products available witho-
ut physicians’ prescription
Increase Increase Possible to implement to Polish healthcare system
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correct use of inhalers, the use of validating test 
to assess the asthma control profile, education 
about healthy lifestyle, conducting the medi-
cation reviews or the advisory in side effects or 
interactions between the drug used in asthma 
and medicinal products available without phy-
sicians’ prescription. Nevertheless, it is directly 
associated with the development of standards 
and recommendations for pharmacists. Other 
services, however, require significant changes in 
the pharmaceutical law.
Recently in Poland the process of develop-
ment the concept of reimbursed pharmaceutical 
care has been launched [42]. Implementing to 
Polish health care system an efficient model for 
pharmaceutical care in various chronic diseases 
may bring the clinical and economic benefits [43]. 
Conclusions
Pharmaceutical care is clinically effective 
in patients diagnosed with asthma. The imple-
mentation of pharmaceutical care under Polish 
conditions is insufficient and challenging for 
the future. Asthma service providers and politics 
(e.g. government) should make a special effort 
in the process of designing and development of 
pharmaceutical services. The process should be 
developed carefully and thoroughly, respecting 
the autonomy of other medical professionals 
and patients’ preferences [44]. It is expected that 
the nearest future will bring the research about 
pharmaceutical care in asthma in Polish reality. 
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